Abstract PTU-179 Table 1

	Combined solid & cystic pNETs (n = 54)	Solid pNETs (n = 44)	Cystic pNETs (n = 10)
Mean Age (yrs)	61.3	61.5	60.2
Sex (Male %)	AB59	AB64	40
Mean size of lesion in cm (range)	2.73 (0.7 – 9.5)	2.95 (0.7 – 9.5)	1.96 (0.8 – 5)
Sensitivity of CT/MRI in detecting pNET (%)	33.3 ¹ @	38.5 ¹ @	10 ¹
Sensitivity of EUS imaging in detecting pNET (%)	51.8 *	57 *	AB30
Sensitivity of EUS cytology in detecting pNET (%)	70.4 @	73 @	AB60
Sensitivity of combined EUS imaging and cytology in detecting pNET(%)	81.5 * ¹	84.1* ¹	70 ¹

Note: * p < 0.05, ¹ p < 0.05, @ p < 0.05 comparison within columns

Conclusion EUS & EUS-FNA is a useful test in diagnosing pNETs. Overall, the sensitivity of combined EUS imaging and cytology was significantly better compared to CT/MRI (p < 0.05) in detecting pNETs across all groups. Sensitivity of combined EUS imaging and cytology was significantly better compared to EUS imaging alone (p < 0.05) in the solid and combined pNET cohort of patients. Sensitivity of EUS cytology was significantly better compared to EUS imaging (p < 0.05) in the solid and combined pNET cohort of patients. Comparing the first 4 years to the second, there has been an increase in the number of cases of pNETs and statistically significant improvement in the diagnostic performance of cytology.

Disclosure of Interest None Declared.

Small bowel

PTU-180 BILE ACID DIARRHOEA – THE GOOD, THE BAD AND EQUIVOCAL RESPONDERS: A TWO CENTRE COMPARISON

doi:10.1136/gutjnl-2013-304907.270

¹A Dhaliwal, ¹S Chambers, ¹C Nwokolo, ²N Williams, ²J Cullis, ³P Basumani, ⁴M Smith, ³K D Bardhan, ¹R Arasardnam. ¹Gastroenterology; ²Radiology, University Hospitals of Coventry and Warwickshire NHS Trust, Coventry; ³Gastroenterology; ⁴Radiology, Rotherham General Hospital NHS Trust, Rotherham, UK

Introduction Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea, currently diagnosed using Se⁷⁵-homo-chloro-tauric-acid (Se⁷⁵HCAAT) testing, the “gold standard” in the UK and available to centres which support a gamma camera. Although the test has been available for over two decades, uptake has been slow despite its diagnostic value and evidence that treatment with sequestrants can be effective. This stems from a lack of formal clinical trials, which encourages a belief the good results reported may reflect patient selection, resulting in therapeutic nihilism. Thus the aim of this study was to compare treatment results between two centres: experienced (α), using data reported earlier, and novice (β), with current data.

Methods The patients recruited comprised those with structural disease (e.g. ileal resection, cholecystectomy), and non-structural, the majority with diarrhoea-predominant irritable bowel syndrome (D-IBS). Abnormal Se⁷⁵HCAAT results were defined as < 10% retention on Day-7. Response to treatment: 1st line (cholestyramine, colestid, colesitol) or 2nd line (colesevelam) was recorded in three categories: good, partial or poor.

Results

Centre α : 2001–2006; recruited n = 162; treatment assessed n = 129. Centre β : 2008–2012; recruited n = 126; treatment assessed n = 99. Response to treatment

Abstract PTU-180 Table

Response	Centre α	Centre β
Good	60 (47%)	40 (40%)
Partial	30 (23%)	23 (23%)
Poor	15 (12%)	10 (10%)

D-IBS – Abnormal Se⁷⁵HCAAT: centre α 33%, Centre β 31%.

Disclosure of Interest None Declared.

Conclusion

- Both centres had similar proportions with abnormal Se⁷⁵HCAAT values, suggesting gastroenterologists are able to select appropriate patients who are likely to benefit from the test.
- Treatment response in both centres was similar, ~70% responding. This suggests treatment is genuinely effective and not limited only to centres with a special interest.

PTU-181 THE LOW DIAGNOSTIC YIELD OF NON-TARGETED DUODENAL BIOPSIES

doi:10.1136/gutjnl-2013-304907.271

¹A Young, ¹C Robertson, ²A A Shah, ¹M Balsitis. ¹Pathology; ²Medicine, Crosshouse Hospital, Kilmarnock, UK

Introduction Duodenal mucosa of normal endoscopic appearance is often biopsied (non-targeted biopsy) to exclude coeliac disease (CD) as the cause of iron deficiency anaemia or other symptoms. Our aim was to investigate the incidence of diagnosis of CD in non-targeted biopsies, in conjunction with tissue transglutaminase antibody (tTG) test results, in 3 adult age groups.

Methods Review of records of 297 consecutive patients having duodenal biopsy from July to October 2011. Age, indication for endoscopy, endoscopic appearance, tTG status and microscopy findings were recorded.

Results See table. Of 297 total patients, age range was 16–93 years. 60 biopsies (20%) were from endoscopically abnormal duodenum and 237 (80%) were from endoscopically normal duodenum, the latter including 12 from patients with follow-up of known CD and 7 with other clinical indication to biopsy normal duodenum. Therefore 218 (73%) were non-targeted biopsies with no indication to biopsy normal duodenum other than to rule out CD. 210 (96%) of the non-targeted biopsies were histologically normal or near normal with no features of CD & the remaining 8 (4%) had histological features consistent with CD. All 8 such patients had positive tTG results, 4 before & 4 after endoscopy, confirming the diagnosis of CD. 60 further patients from the 218 non-targeted group had tTG testing and all were negative. 65 (30%) non-targeted biopsies were from patients aged ≥ 75 years but CD was not newly diagnosed in this age group. 3 of the 60 patients with endoscopically abnormal duodenum had histological features consistent with a new diagnosis of CD and positive tTG (≤ 54 years = 1, 55–74 years = 2, ≥ 75 years = 0).

Conclusion The majority of duodenal biopsies were non-targeted. CD was identified in 4% of non-targeted biopsies, in tTG positive patients. Non-targeted biopsies did not show significant findings in tTG negative patients. Reduction in biopsy workload could be achieved if non-targeted biopsies were to be taken only in the setting of positive tTG or other relevant clinical indication; no